Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Psychedelic Titans

27 Jul 2021

Psychedelic Titans with Benjamin Lightburn of Filament Health

This week's Psychedelic Titan is Benjamin Lightburn, CEO & Co-Founder of Filament Health, a natural psychedelic drug development company....

By Microdose

Psychedelic Groundbreakers

22 Jul 2021

Psychedelic Groundbreakers: Mycrodose Therapeutics

This week's Psychedelic Groundbreaker is Mycrodose Therapeutics, dedicated to helping fight the mental health global pandemic....

By Microdose

Psychedelic Titans

20 Jul 2021

Psychedelic Titans with Belinda Tan of People Science

This week's Psychedelic Titan is Belinda Tan, Co-founder & Co-CEO for People Science that is bringing better science to alternative medicine....

By Microdose

Press Releases

17 Jul 2021

The Newly Institute Announces the Execution of a Joint Working Agreement with Drug Science for the Drug Science Medical Psychedelics Working Group

The Drug Science Medical Psychedelics Working Group is a consortium of Drug Science experts, industry partners, patient representatives and policymakers...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

7 Jul 2021

Amanda Galbraith, Principal at Navigator Joins the Board of Psyched Wellness

Toronto, Ontario--(Newsfile Corp....

By Microdose

Press Releases

30 Jun 2021

Psyched Wellness Announces Matthew Singh Joins Team as CPG and Branding Consultant

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

30 Jun 2021

Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

30 Jun 2021

Maxim Group Initiates Coverage of Mind Cure Health

Maxim Group Initiates Coverage on 10 Psychedelic Stocks including MindMed, Compass Pathways, Cybin, Field Trip, Mydecine, Mind Cure etc....

By Microdose

Press Releases

28 Jun 2021

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Investigator, The Lundquist InstituteProfessor of Psychiatry & Biobehavioral Sciences and Pediatrics, David Geffen School of Medicine at UCLA Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.